Navigation Links
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
Date:11/4/2008

anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website ( http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).

http://www.nicox.com


'/>"/>
SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1082

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
8. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
11. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... in the Tel Aviv area ... promote WuXi,s broad platform of integrated R&D services to ...
(Date:10/30/2014)... -- The number of retail health clinics in ... to drug store chains, according to Kalorama Information.  In ... retail clinic growth had been at a standstill, but ... of retail clinics reached nearly 1,600 according to the ... and 2014 Consumer Survey Results .  More ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Genmab A/S (CSE: GEN),announced today that the results ... patients with rheumatoid,arthritis (RA) have been accepted for ... Rheumatology (EULAR). The oral,presentation, which will include new ... with ofatumumab, along with data,from the previous interim ...
... Study Shows At Least 10 Genetic Variants Are ... 26, 2007 – In the most,comprehensive look at ... a U.S.-Finnish team, working in close collaboration with ... genetic variants,associated with increased risk of diabetes and ...
Cached Medicine Technology:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 7
(Date:10/30/2014)... Don Allred Insurance, a leading provider of ... North Carolina residents, is excited to announce the Grand ... Mall. The new branch has been up and running ... all facets of the insurance selection process from quote ... Allred couldn’t be happier with the timing of this ...
(Date:10/30/2014)... Five months after their expansion, the ... announces new branding and a website to accompany their ... David Mepham’s promotion to name partner earlier this year, ... include Mepham’s name and better reflect their combined litigation ... the decision to implement new branding reflects Hodgkinson Street ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... Ebola outbreak in Liberia -- one of three West African ... Health Organization officials said Wednesday. Dr. Bruce Aylward, WHO,s ... number of burials in Liberia and no increase in laboratory-confirmed ... push to tame the epidemic may be making some progress, ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... better known for their close association to fishes has ... ,Dietary intake of omega 3 fatty acids such ... may curb the growth of breast cancer cells, ... of Cancer., ,Min Wu and colleagues at Methodist ...
... study in USA to see if the procedures of ... ,The study will enroll of more than 16,000 ... be safely performed in smaller, community hospitals, easing access ... the first study patients in early fall 2005. ...
... cancer remain the most feared diseases all around the ... inhaler, potentially offering adult diabetics an alternative to injections// ... to be approved by the FDA. ,If approved, ... to the insulin injections taken by millions worldwide. The ...
... people may accelerate the heart conditions by releasing the levels ... of 32 people with heart failure, the 14 patients who ... this protein in their blood. ,The protein, tumor necrosis ... of proteins called cytokines, chemical messengers that are mobilized when ...
... Research suggests that 25% of the MRSA infections in the ... the hospital. The research was published in the latest ... many sites; one serious form of infection is that in ... scheme counts MRSA bacteremia by hospital trust, but it has ...
... doctors of American Origin are helping out the victims from ... members of the American Association of Physicians of Indian Origin// ... US who number over 25,000 - have volunteered their services ... Mississippi and Alabama. ,The volunteers hail from almost all ...
Cached Medicine News:Health News:Exubera could mean the end of an insulin injection era for diabetics 2Health News:Indian doctors in America help Katrina victims 2
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Fujinon's standard fiberoptic bronchoscope is fully submersible and offers a large image for more comfortable and efficient observation....
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
... The BF-1T40 has been designed with a ... in therapeutic applications. This permits the selection ... those for electrosurgical procedures. In addition, this ... field of view and a bright, high-resolution ...
Medicine Products: